OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Hematology is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	325
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination	324
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management	209
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures	197
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management	178
BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies	141
Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine	131
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management	128
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA	128
Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis	120
Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy	116
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management	113
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring	110
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study	104
Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccine	92
Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY	86
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management	85
Recommendations for diagnosis and treatment of methemoglobinemia	81
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management	81
POEMS syndrome: 2021 Update on diagnosis, risk‐stratification, and management	80
Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation	73
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma	71
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality	71
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments	64
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1	64

Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castlema	62
Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment	61
Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life	59
Increased blood viscosity and red blood cell aggregation in patients with COVID‐19	58
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management	57
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell	55
Hepcidin levels predict Covid‐19 severity and mortality in a cohort of hospitalized Italian patients	55
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment	55
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report	51
Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphoma	50
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management	50
Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine	49
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients	49
Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases	48
Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors	46
Cerebral venous thrombosis post BNT162b2 mRNA SARS‐CoV‐2 vaccination: A black swan event	44
Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist	42